Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1996-07-26
2001-08-14
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C424S009200, C435S018000, C435S019000, C435S021000, C435S029000, C435S032000, C436S063000, C436S071000, C800S003000
Reexamination Certificate
active
06274309
ABSTRACT:
1. INTRODUCTION
The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.
2. BACKGROUND
The sphingomyelin pathway is a ubiquitous, evolutionarily conserved signaling system initiated by hydrolysis of sphingomyelin to generate the second messenger ceramide. Two forms of sphingomyelinase, distinguishable by the pH optima, are capable of initiating signaling. Acid sphingomyelinase (pH optimum 4.5-5.0) was originally identified as a lysosomal hydrolase required for turnover of cellular membranes (for review see Kolesnick, R. N., 1991, Prog. Lipid Res. 30 1-38). However, Kronke and co-workers proposed that this enzyme was also targeted to the plasma membrane and signaled in response to activation of the 55 kD TNF receptor (Wiegmann, K. et al., 1994, Cell 78:1005-1015). Activation of acid sphingomyelinase has also now been associated with signaling via Fas, CD28 and the interleukin (IL)-1 receptor (Cifone, et al., 1993., J. Exp. Med. 177:1547-1552; Boucher, L.-M. et al., 1995, J. Exp. Med. 181:2059-2068.; Liu. P. & Anderson, R. G. W., et al., 1995, J. Biol. Chem. 270:27179-27185. Human acid sphingomyelinase is the product of a single gene, although alternative processing of the primary transcript allows for the generation of multiple forms (Schuchman, E. H., et al., 1991, J. Biol. Chem. 266:8531-8539; Schuchman, E. H., et al., 1992, Genomics 12:197-205. Inherited mutations of the human acid sphingomyelinase gene lead to enzyme deficiency and the genetic disorder known as Niemann Pick disease (NPD; Brady et al., R. O., et al., 1966, Proc. Natl. Acad. Sci. USA 55, 366-369.; Schneider, P. B. & Kennedy, E. P., 1967, J. Lipid Res. 8:202-209.
Neutral sphingomyelinase (pH optimum 7.4) was originally defined as a Mg2
+
-dependent enzyme localized to the outer leaflet of the plasma membrane (Rao, B. G. & Spence, M. W., 1976, J. Lipid Res. 17:506-515.; Yedger, S. & Gatt, S., 1976. Biochemistry 15:2570-2573. However, a Mg2
+
-independent isoform of neutral sphingomyelinase which localizes to the cytoplasm has recently been identified (Okazaki, T. et al., 1989, J. Biol. Chem. 264:19076-19080.; Okazaki, T. et al., 1994, J. Biol. Chem. 269:4070-4077.). The neutral sphingomyelinase has not yet been characterized at the molecular level.
Neutral sphingomyelinase activation has been demonstrated in response to cellular stimulation with TNFa (Wiegmann, K. et al., 1994, Cell 78:1005-1015) anti-Fas antibody (Tepper, C. G., et al., 1995, Proc. Natl. Acad. Sci. USA 92:8443-8447.; Cifone, M. G. et al., 1995, EMBO J. 14:5859-5868.), and vitamin D (Okazaki, T. et al., 1989, J. Biol. Chem. 264:19076-19080; Okazaki, T. et al., 1994, J. Biol. Chem. 269:4070-4077.). It has also been suggested that neutral sphingomyelinase signals in response to IL-1b (Mathias, S. et al., 1993, Science 259:519-522) and ionizing radiation (Halmovitz-Friedman, A. et al., 1994, J. Exp. Med. 180:525-535.).
Although ceramide has been implicated as the second messenger for a variety of stress stimuli including TNFa, Fas ligand, ionizing radiation, heat shock, ultraviolet light and oxidative stress (Obeid, L. M. et al., 1993, Science 259:1769-1771.; Cifone, M. G. et al., 1993, J. Exp. Med. 177:1547-1552.; Jarvis, W. D., et al., 1994, Proc. Natl. Acad. Sci. USA 91:73-77; Fuks, Z., et al., 1994, Cancer Res. 54:2582-2590; Halmovitz-Friedman, A., et al., 1994, J. Exp. Med. 180:525-535.; Gulbins, E. et al., 1995, Immunity 2:341-351.; Verheij, M. et al., 1996, Nature 380:75-79; Jarvis, W. D. et al., 1996, Clin. Cancer Res. 2:1-6). Evidence for such speculation has been circumstantial (Verheij, M. et al., 1996, Nature 380:75-79; Hannun, Y. A. & Obeid, L. M, 1995, Trends Biochem. Sci. 20:73-77). Definitive proof, therefore, that ceramide generation is a primary mediator of the apoptotic response is lacking.
3. SUMMARY OF THE INVENTION
The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis.
The present invention is based, in part, on the surprising discovery, described in the Example presented in Section 6, below, that acid sphingomyelinase activity is required for activation of stress-induced apoptotic cellular pathways. Specifically, the data presented in these Examples shows that ASM-deficient cell lines and ASM-deficient animals are resistant to radiation-induced apoptosis. Thus, the data described herein define, for the first time, an obligatory role for ceramide generation in signalling of stress-induced apoptosis.
The present invention further relates to methods for the identification of compounds which modulate ASM-related processes, including apoptosis. “Modulation” as used herein, can refer, first, to an increase in the sensitivity of cells, specially neoplastic cells, to ASM-related processes, including apoptosis. Alternatively, “modulation” can refer to a decrease in the sensitivity of cells to ASM-related processes such as apoptosis; e.g., can refer to an increase in the cells' resistance to apoptosis.
Methods for the identification of compounds which increase a cell's sensitivity to ASM-related processes such as apoptosis can be performed to identify targets and compounds which mimic ASM or act downstream of ASM in apoptotic pathways. Among the compounds and targets identified via such identification methods are agents which can be utilized to increase a neoplastic cell's sensitivity to apoptosis, thereby improving the clinical effects of anti-cell proliferative therapy, e.g. radiation and/or chemotherapeutic therapies.
Such methods can include, for example, a method comprising, first contacting an acid sphingomyelinase-deficient cell with a test compound, exposing the cell to a stress stimulus for a time sufficient to induce apoptosis in a cell exhibiting normal acid sphingomyelinase activity. Second, an acid sphingomyelinase-deficient cell is exposed, in the absence of the test compound, to the stress stimulus for a time sufficient to induce apoptosis in a cell exhibiting normal acid sphingomyelinase activity. The exposed cells are monitored for the presence of an apoptotic morphology, such that if the cell exposed to the test compound exhibits a more severe apoptotic morphology, the test compound represents a compound which increases a cell's sensitivity to acid sphingomyelinase-related apoptosis.
Alternatively, such methods for identifying a compound which increases a cell's sensitivity to acid sphingomyelinase-related apoptosis can also comprise, first, contacting an acid sphingomyelinase-deficient cell with a test compound, and exposing the cell to a stress stimulus. Next, an acid sphingomyelinase-deficient cell is exposed, in the absence of the test compound, to the stress stimulus. The levels of sphingomyelin and ceramide present in the exposed cells are compared, such that if the level of sphingomyelin in the cell exposed in presence of test compound is less than that of the cell exposed in the absence of the test compound, or the level of ceramide in the cell exposed in the presence of test compound is greater than that of the cell exposed in the absence of test compound, the test compound represents a comp
Kolesnick Richard
Schuchman Edward H.
Pennie & Edmonds LLP
Saunders David
LandOfFree
Method for the modulation of acid-sphingomyelinase-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the modulation of acid-sphingomyelinase-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the modulation of acid-sphingomyelinase-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2499406